Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director | June 10, 2026 | June 18, 2026 |
| Virpax Pharmaceuticals, Inc.VRPX · Entity 84306 | Director | July 05, 2024 | July 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date June 10, 2026 · Filed June 18, 2026
This filing explicitly reported no securities owned.
Virpax Pharmaceuticals, Inc.
Report date July 05, 2024 · Filed July 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2034-07-04 | Direct | 2,500 |
Reported balance
After 2024-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-05 · Grant · Acquired 2,500 · Balance 2,500 F1: The option vests in full on the twelve-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the twelve-month anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LQR House Inc.
Report date October 14, 2024 · Filed October 16, 2024
Section 16 reporting ended · disclosed 2024-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-10-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-14 · Disposition to issuer · Disposed 500 · Balance 0 F2: N/A. F1: A disposition of restricted stock units ("RSU") reported reflects the forfeiture of the unvested portion of the RSUs in connection with Mr. Dhaliwal's resignation as a director of LQR House Inc., effective October 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: A disposition of restricted stock units ("RSU") reported reflects the forfeiture of the unvested portion of the RSUs in connection with Mr. Dhaliwal's resignation as a director of LQR House Inc., effective October 14, 2024.
F2: N/A.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2024 Filed Oct 16, 2024 20:05 UTC | LQR House Inc. LQR · Entity 8513 | Disposition to issuerRestricted Stock Units · Derivative | 500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-088165 · ownership.xml · derivative · entry 1 Dhaliwal Jatinder · CIK 0002018476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires not disclosed F2 · derivative.exercise_price: N/A. F1 · kind: A disposition of restricted stock units ("RSU") reported reflects the forfeiture of the unvested portion of the RSUs in connection with Mr. Dhaliwal's resignation as a director of LQR House Inc., effective October 14, 2024. F2 · price: N/A. F2 · derivative.exercise_date: N/A. F2 · derivative.expiration_date: N/A. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:02 UTC | Virpax Pharmaceuticals, Inc. VRPX · Entity 84306 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001213900-24-060119 · ownership.xml · derivative · entry 1 Dhaliwal Jatinder · CIK 0002018476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2034-07-04 F1 · derivative.exercise_date: The option vests in full on the twelve-month anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.